INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $111,234,809 | -16.6% | 2,135,435 | +1.4% | 0.01% | -14.3% |
| Q2 2023 | $133,333,241 | +21.5% | 2,105,705 | +3.9% | 0.01% | +16.7% |
| Q1 2023 | $109,720,246 | -48.0% | 2,026,228 | -49.2% | 0.01% | 0.0% |
| Q4 2022 | $211,151,118 | +129.6% | 3,990,006 | +101.9% | 0.01% | 0.0% |
| Q3 2022 | $91,954,000 | -16.1% | 1,976,223 | +2.9% | 0.01% | -14.3% |
| Q2 2022 | $109,583,000 | -0.1% | 1,919,815 | +7.1% | 0.01% | +40.0% |
| Q1 2022 | $109,685,000 | +37.6% | 1,792,530 | +17.7% | 0.01% | +25.0% |
| Q4 2021 | $79,695,000 | +36.7% | 1,522,638 | -2.6% | 0.00% | +33.3% |
| Q3 2021 | $58,283,000 | -4.8% | 1,563,375 | +4.2% | 0.00% | 0.0% |
| Q2 2021 | $61,231,000 | +21.6% | 1,500,029 | +1.1% | 0.00% | 0.0% |
| Q1 2021 | $50,341,000 | -1.8% | 1,483,659 | -8.0% | 0.00% | 0.0% |
| Q4 2020 | $51,281,000 | +40.7% | 1,612,601 | +13.6% | 0.00% | +50.0% |
| Q3 2020 | $36,435,000 | +4.0% | 1,419,918 | +4.1% | 0.00% | -33.3% |
| Q2 2020 | $35,028,000 | +84.6% | 1,364,536 | +10.5% | 0.00% | +50.0% |
| Q1 2020 | $18,979,000 | -50.3% | 1,234,814 | +10.9% | 0.00% | -33.3% |
| Q4 2019 | $38,202,000 | +342.0% | 1,113,444 | -3.8% | 0.00% | +200.0% |
| Q3 2019 | $8,643,000 | -33.4% | 1,157,047 | +15.8% | 0.00% | 0.0% |
| Q2 2019 | $12,968,000 | +7.5% | 999,100 | +0.9% | 0.00% | 0.0% |
| Q1 2019 | $12,060,000 | +3.3% | 990,169 | -3.4% | 0.00% | 0.0% |
| Q4 2018 | $11,674,000 | -46.5% | 1,024,944 | +2.0% | 0.00% | -50.0% |
| Q3 2018 | $21,801,000 | +31.4% | 1,004,622 | +7.0% | 0.00% | +100.0% |
| Q2 2018 | $16,592,000 | -13.3% | 939,034 | +3.2% | 0.00% | -50.0% |
| Q1 2018 | $19,143,000 | +38.3% | 909,522 | -4.8% | 0.00% | +100.0% |
| Q4 2017 | $13,837,000 | +18.8% | 955,465 | +29.5% | 0.00% | 0.0% |
| Q3 2017 | $11,647,000 | -6.6% | 737,763 | -26.5% | 0.00% | 0.0% |
| Q2 2017 | $12,474,000 | -15.6% | 1,004,360 | +10.4% | 0.00% | 0.0% |
| Q1 2017 | $14,786,000 | +0.7% | 909,597 | -6.5% | 0.00% | 0.0% |
| Q4 2016 | $14,686,000 | +16.9% | 972,868 | +18.0% | 0.00% | 0.0% |
| Q3 2016 | $12,562,000 | -58.7% | 824,123 | +5.1% | 0.00% | -66.7% |
| Q2 2016 | $30,437,000 | +31.7% | 783,959 | -5.7% | 0.00% | +50.0% |
| Q1 2016 | $23,112,000 | -46.8% | 831,297 | +3.0% | 0.00% | -60.0% |
| Q4 2015 | $43,428,000 | -8.1% | 807,331 | -31.6% | 0.01% | -16.7% |
| Q3 2015 | $47,253,000 | +391.3% | 1,180,210 | +292.1% | 0.01% | +500.0% |
| Q2 2015 | $9,617,000 | +60.0% | 300,974 | +19.6% | 0.00% | 0.0% |
| Q1 2015 | $6,009,000 | +76.5% | 251,596 | +30.4% | 0.00% | – |
| Q4 2014 | $3,404,000 | +40.2% | 192,941 | +8.9% | 0.00% | – |
| Q3 2014 | $2,428,000 | -16.4% | 177,120 | +2.8% | 0.00% | – |
| Q2 2014 | $2,903,000 | +944.2% | 172,252 | +1025.8% | 0.00% | – |
| Q1 2014 | $278,000 | – | 15,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |